Albert Deisseroth

7.8k total citations · 1 hit paper
139 papers, 5.7k citations indexed

About

Albert Deisseroth is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Albert Deisseroth has authored 139 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 50 papers in Oncology and 41 papers in Hematology. Recurrent topics in Albert Deisseroth's work include Virus-based gene therapy research (32 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Albert Deisseroth is often cited by papers focused on Virus-based gene therapy research (32 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Albert Deisseroth collaborates with scholars based in United States, United Kingdom and Türkiye. Albert Deisseroth's co-authors include Wei Zhang, Arthur W. Nienhuis, Philip A. Pizzo, Richard Pazdur, Ann T. Farrell, Wei Zhang, Daniel G. Wright, Sybil M. Santee, James C. Cusack and Weiwei Zhang and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Albert Deisseroth

136 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression

1995 615 citations Laurie B. Owen‐Schaub, Wei Zhang et al. Molecular and Cellular Biology profile →

Peers

Countries citing papers authored by Albert Deisseroth

Since Specialization

Citations

This map shows the geographic impact of Albert Deisseroth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Deisseroth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Deisseroth more than expected).

Fields of papers citing papers by Albert Deisseroth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Deisseroth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Deisseroth. The network helps show where Albert Deisseroth may publish in the future.

Co-authorship network of co-authors of Albert Deisseroth

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Deisseroth. A scholar is included among the top collaborators of Albert Deisseroth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Deisseroth. Albert Deisseroth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation 2019 ·Clinical Cancer Research ·Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E. Dorff, Donna Przepiorka, Albert Deisseroth, Yuan Li Shen, Christopher M. Sheth, Rosane Charlab, Gene M. Williams, Kirsten B. Goldberg, Ann T. Farrell, Richard Pazdur	102
2	FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease 2019 ·The Oncologist ·Donna Przepiorka, Lola Luo, Sriram Subramaniam, Junshan Qiu, Ramadevi Gudi, Lea Cunningham, Lei Nie, Rupert W. Leong, Lian Ma, Christopher M. Sheth, Albert Deisseroth, Kirsten B. Goldberg, Gideon M. Blumenthal, Richard Pazdur	91
3	FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease 2018 ·Clinical Cancer Research ·Emily Y. Jen, (unknown), Aaron J. Schetter, Donna Przepiorka, Yuan Li Shen, Donna Roscoe, Rajeshwari Sridhara, Albert Deisseroth, Reena Philip, Ann T. Farrell, Richard Pazdur	98
4	FDA Approval: Blinatumomab 2015 ·Clinical Cancer Research ·Donna Przepiorka, Chia‐Wen Ko, Albert Deisseroth, Carolyn L. Yancey, (unknown), Haw-Jyh Chiu, Brenda J. Gehrke, (unknown), Robert C. Kane, Susan Kirshner, Nitin Mehrotra, Tiffany K. Ricks, Deborah H. Schmiel, Pengfei Song, Ping Zhao, Qing Zhou, Ann T. Farrell, Richard Pazdur	261
5	Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged 2009 ·Cancer Immunology Immunotherapy ·(unknown), Marilyn L. Thoman, Phyllis‐Jean Linton, Albert Deisseroth	19
6	Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells 2007 ·Human Pathology ·(unknown), Ying Liu, (unknown), (unknown), Je Ho Lee, (unknown), Albert Deisseroth	20
7	Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy 2007 ·Molecular Therapy ·Barbara‐ann Guinn, Noriyuki Kasahara, Farzin Farzaneh, Nagy Habib, James S. Norris, Albert Deisseroth	24
8	Vector Prime/Protein Boost Vaccine That Overcomes Defects Acquired during Aging and Cancer 2006 ·The Journal of Immunology ·Yucheng Tang, Hakan Akbulut, (unknown), (unknown), Xiangming Fang, Weiwei Zhang, Xiao-Qin Xia, James A. Koziol, Phyllis‐Jean Linton, Albert Deisseroth	12
9	An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells 2003 ·Proceedings of the National Academy of Sciences ·Lixin Zhang, Yucheng Tang, Hakan Akbulut, Daniel Zelterman, Phyllis‐Jean Linton, Albert Deisseroth	56
10	Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon 2003 ·Cancer Gene Therapy ·Hakan Akbulut, Lixin Zhang, Yucheng Tang, Albert Deisseroth	42
11	Direct PCR Sequencing with Denaturants (Formamide) 2003 ·Humana Press eBooks ·Wei Zhang, Albert Deisseroth	1
12	Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma 2000 ·JNCI Journal of the National Cancer Institute ·Gabriel N. Hortobagyi, Aman U. Buzdar, Richard L. Theriault, Vicente Valero, Debra Frye, Daniel J. Booser, Frankie A. Holmes, S. Giralt, Issa F. Khouri, B Andersson, James Gajewski, Gabriela Rondón, Terry L. Smith, S. Eva Singletary, Frederick C. Ames, Nour Sneige, E. A. Strom, Marsha D. McNeese, Albert Deisseroth, Richard Champlin	126
13	Hematopoietic Retroviral Gene Marking in Patients with Follicular Non-Hodgkin's Lymphoma 1999 ·Leukemia & lymphoma ·Carlos Bachier, Richard E. Giles, (unknown), (unknown), F. García‐Sánchez, Michael Andreeff, Fernando Cabanillas, Richard Champlin, (unknown), Ronald Berenson, Shelly Heimfeld, Albert Deisseroth	17
14	Principles of Bone Marrow Processing and Progenitor Cell/Mononuclear Cell Concentrate Collection in a Continuous Flow Blood Cell Separation System 1995 ·Journal of Hematotherapy ·Jeane P. Hester, Gabriela Rondón, Yang O. Huh, (unknown), Richard E. Champlin, Albert Deisseroth	3
15	Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression breakdown → 1995 ·Molecular and Cellular Biology ·Laurie B. Owen‐Schaub, Wei Zhang, James C. Cusack, Laura S. Angelo, Sybil M. Santee, Toshiyoshi Fujiwara, Jack A. Roth, Albert Deisseroth, Weiwei Zhang, Ewa Kruzel, Robert Radinsky	615
16	Hemopoietic growth factors, oncogenes, and cytokines in clinical hematology : current aspects and future directions 1994 ·KARGER eBooks ·(unknown), Albert Deisseroth, Rosario Giustolisi	1
17	Molecular approaches to the diagnosis and treatment of cancer 1993 ·Stem Cells ·Albert Deisseroth, Hagop M. Kantarjian, Moshe Talpaz, Richard Champlin, Christopher L. Reading, Elie G. Hanania, Siqing Fu, Gurvaneet Randhawa, Ying Cha, Xiangming Fang, Steven M. Kornblau, N. Pollicardo, Wei Zhang	1
18	Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia 1991 ·Cancer ·Hagop M. Kantarjian, C. Frederick LeMaistre, Jorge A. Spinolo, Gary Spitzer, J. Yau, Karel A. Dicke, Sundar Jagannath, Albert Deisseroth, Moshe Talpaz	28
19	Interleukin-2, Cisplatin, and 5-Fluorouracil for Patients with Non-Small Cell Lung and Head/Neck Carcinomas 1991 ·Journal of Immunotherapy ·Frank H. Valone, David R. Gandara, Albert Deisseroth, Edith A. Perez, Anthony A. Rayner, Frederick R. Aronson, Judith Luce, Carolyn Paradise	25
20	Regulation of adult and embryonic genes in human leukemia cells 1987 ·American Journal of Hematology ·Albert Deisseroth, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact